ARCH
Discipline of Obstetrics and Gynaecology
The University of Adelaide

Women's and Children's Hospital
King William Road
North Adelaide SA 5006
AUSTRALIA
Email

Phone: +61 8 8161 7619
Facsimile: +61 8 8161 7652

MAGENTA: Magnesium sulphate at 30 to 34 weeks' gestational Age: Neuroprotection Trial.

ACTRN12611000491965

This trial is currently recruiting. The trial is open for other centres to join the study.

Babies born very preterm have a greater risk of significant morbidities including neurologic impairments such as cerebral palsy. The risk of morbidity increases with decreasing gestational age at birth. The Cochrane review evaluating the effect of magnesium sulphate on neuroprotection of the fetus shows that magnesium sulphate given to women at risk of imminent preterm birth reduces the risk of cerebral palsy. It remains unclear at which gestational age treatment will be beneficial.

The National Clinical Practice Guidelines on Antenatal Magnesium Sulphate prior to preterm birth of the fetus, infant and child recommends further randomised trials at 30 weeks' gestation or more. This had led to the MAGENTA Study.

Funding:	NHMRC Project Grant 2012-2016
Chief Investigators:	Professor Caroline Crowther, Ms Philippa Middleton, A/Professor Dominic Wilkinson, A/Professor Ross Haslam
Clinical Trial Coordinator:	Ms Pat Ashwood
Email:	magenta@adelaide.edu.au
Address:	Contact Us
Phone:	61 8 8161 7767
Fax:	61 8 8161 7652
Collaborating Centres:
Australia	SA - Women's & Children's Hospital Flinders Medical Centre NSW - Royal North Shore Hospital St George Hospital QLD - Mater Mother's Hospital Royal Brisbane & Women's Hospital Townsville Hospital Ipswich Hospital VIC - Royal Women's Hospital Mercy Hospital for Women Monash Medical Centre TAS - Royal Hobart Hospital
New Zealand	Auckland City Hospital Waikato Hospital Christchurch Hospital Middlemore Hospital

References

Doyle L, Crowther C, Middleton P, Voysey M, Marret S, Rouse D. Antenatal magnesium sulphate to prevent cerebral palsy in very preterm infants. BJOG 2011;118(7):891-892.
Nguyen TN, Crowther CA, Wilkinson D. Magnesium sulphate for women at term for neuroprotection of the fetus (Protocol). Cochrane Database Syst Rev. 2011(10).
Antenatal Magnesium Sulphate for Neuroprotection Guideline Development Panel. Antenatal magnesium sulphate prior to preterm birth for neuroprotection of the fetus, infant and child: National clinical practice guidelines. 2010 Adelaide, The University of Adelaide (Guidelines)
Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev. 2010(1).
Doyle L, Crowther C. et al. Antenatal magnesium sulphate and neuroprotection for very preterm infants - The Updated Cochrane review. J Paediatrics and Child Health 2009;45(suppl 1): A47
Crowther CA, Doyle LW. et al. Outcomes at 2 years of age after repeat doses of antenatal corticosteroids. New Engl J Med 2007;357(12): 1179-1189.
Crowther, CA, JE. Hiller, et al. Effect of magnesium sulfate given for neuroprotection before preterm birth - A randomized controlled trial. JAMA 2003;290(20): 2669-2676.
Crowther CA, Hiller JE. et al. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane database Syst Rev 2002. Issue 4. Art. No.: CD001060. DOI: 10.1002/14651858.CD001060.